Literature DB >> 24928831

Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030.

R Brinks1, R Fischer-Betz2, O Sander2, J G Richter2, G Chehab2, M Schneider2.   

Abstract

OBJECTIVE: The objective of this report is to estimate the prevalence and future number of cases of systemic lupus erythematosus (SLE) in Germany.
METHODS: Data from a representative sample of all insurants from the statutory health insurance in Germany comprising more than 2.3 million individuals have been screened for SLE diagnoses. The gender- and age-specific prevalence of SLE is calculated. The case definition is based on at least one recorded diagnosis of SLE during 2002. The stratum-specific prevalence is applied to the current and the future population of Germany in order to estimate and predict the number of people with SLE until 2030.
RESULTS: The overall prevalence of diagnosed SLE in 2002 was 15.4 (95% CI: 13.1-17.9) and 55.4 (51.4, 59.8) per 100,000 in the male and female German population. This corresponds to an estimated 30,000 and 31,000 people with diagnosed SLE in 2002 and 2010, respectively. This number will slightly increase until 2020 and decrease thereafter.
CONCLUSIONS: Compared with health insurance data from France, the prevalence in our data is similar. Under the assumption that the gender- and age-specific prevalence of SLE in Germany will not change considerably, the number of cases in the next two decades will change only slightly.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Germany; Systemic lupus erythematosus; prevalence; projections and predictions

Mesh:

Year:  2014        PMID: 24928831     DOI: 10.1177/0961203314540352

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  The Diagnosis and Treatment of Systemic Lupus Erythematosus.

Authors:  Annegret Kuhn; Gisela Bonsmann; Hans-Joachim Anders; Peter Herzer; Klaus Tenbrock; Matthias Schneider
Journal:  Dtsch Arztebl Int       Date:  2015-06-19       Impact factor: 5.594

Review 2.  [Systemic lupus erythematosus-are children small adults?]

Authors:  Tobias Alexander; Christian M Hedrich
Journal:  Z Rheumatol       Date:  2021-11-08       Impact factor: 1.372

3.  Anti-nuclear autoantibodies in the general German population: prevalence and lack of association with selected cardiovascular and metabolic disorders-findings of a multicenter population-based study.

Authors:  Manas K Akmatov; Nadja Röber; Wolfgang Ahrens; Dieter Flesch-Janys; Julia Fricke; Halina Greiser; Kathrin Günther; Rudolf Kaaks; Yvonne Kemmling; Bastian Krone; Jakob Linseisen; Christa Meisinger; Susanne Moebus; Nadia Obi; Carlos A Guzman; Karsten Conrad; Frank Pessler
Journal:  Arthritis Res Ther       Date:  2017-06-06       Impact factor: 5.156

4.  Gene-set meta-analysis of lung cancer identifies pathway related to systemic lupus erythematosus.

Authors:  Albert Rosenberger; Melanie Sohns; Stefanie Friedrichs; Rayjean J Hung; Gord Fehringer; John McLaughlin; Christopher I Amos; Paul Brennan; Angela Risch; Irene Brüske; Neil E Caporaso; Maria Teresa Landi; David C Christiani; Yongyue Wei; Heike Bickeböller
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

5.  Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?

Authors:  Raúl Cortés Verdú; José M Pego-Reigosa; Daniel Seoane-Mato; Mercedes Morcillo Valle; Deseada Palma Sánchez; María J Moreno Martínez; Marta Mayor González; Joana Atxotegi Sáenz de Buruaga; Irati Urionagüena Onaindia; Boris A Blanco Cáceres; Lucía Silva-Fernández; Francisca Sivera; Francisco J Blanco; Carlos Sánchez-Piedra; Federico Díaz-González; Sagrario Bustabad
Journal:  Rheumatology (Oxford)       Date:  2020-09-01       Impact factor: 7.580

6.  The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization.

Authors:  Andreas Schwarting; Heiko Friedel; Elena Garal-Pantaler; Marc Pignot; Xia Wang; Henk Nab; Barnabas Desta; Edward R Hammond
Journal:  Rheumatol Ther       Date:  2021-02-05

7.  [Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC)].

Authors:  Carsten Oliver Schmidt; Klaus-Peter Günther; Jens Goronzy; Katinka Albrecht; Jean-François Chenot; Johanna Callhoff; Adrian Richter; Richard Kasch; Wolfgang Ahrens; Heiko Becher; Klaus Berger; Hermann Brenner; Beate Fischer; Claus-Werner Franzke; Wolfgang Hoffmann; Bernd Holleczek; Lina Jaeschke; Carsten Jenning; Karl-Heinz Jöckel; Rudolf Kaaks; Thomas Keil; Alexander Kluttig; Gérard Krause; Oliver Kuß; Michael Leitzmann; Wolfgang Lieb; Jakob Linseisen; Markus Löffler; Claudia Meinke-Franze; Christa Meisinger; Karin B Michels; Rafael Mikolajczyk; Nadia Obi; Annette Peters; Tobias Pischon; Tamara Schikowski; Sabine Schipf; Christof Specker; Henry Völzke; Kerstin Wirkner; Angela Zink; Oliver Sander
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-04       Impact factor: 1.513

8.  Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002.

Authors:  Ralph Brinks; Annika Hoyer; Sergej Weber; Rebecca Fischer-Betz; Oliver Sander; Jutta G Richter; Gamal Chehab; Matthias Schneider
Journal:  Lupus Sci Med       Date:  2016-11-25

9.  The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis.

Authors:  Tilman Hottenrott; Rick Dersch; Benjamin Berger; Dominique Endres; Daniela Huzly; Jens Thiel; Sebastian Rauer; Oliver Stich; Ulrich Salzer; Nils Venhoff
Journal:  BMC Neurol       Date:  2018-01-31       Impact factor: 2.474

10.  Illness-Death Model in Chronic Disease Epidemiology: Characteristics of a Related, Differential Equation and an Inverse Problem.

Authors:  Ralph Brinks
Journal:  Comput Math Methods Med       Date:  2018-09-12       Impact factor: 2.238

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.